![Michael Vaezi MD, PhD, MS, MACG](https://res.cloudinary.com/els-assets/image/upload/c_fill_pad,f_auto,g_auto,h_150,q_auto,w_120/v1/practice-update/remote-media/contentimage/46334.jpg)
Michael F. Vaezi MD, PhD, MS, MACG
Professor of Medicine and Otolaryngology; Associate Chief and Clinical Director, Division of Gastroenterology, Hepatology and Nutrition; Director, Clinical Research and Esophageal Center, Vanderbilt University Medical Center, Nashville, TennesseeDr. Vaezi is currently a Professor of Medicine and Otolaryngology at the Vanderbilt University Medical Center in the Division of Gastroenterology, Hepatology and Nutrition. He is the Associate Chief and Clinical Director of the Division and Director of Center for Swallowing and Esophageal Disorders and Director of Clinical Research. He is the past Chair of the EGD Section of the AGA and the outgoing Associate Editor for Gastroenterology and member of the AGA research Council.
Dr. Vaezi received a B.S. degree in Chemistry at Birmingham-Southern College in Birmingham, Alabama. He then went to the University of Alabama at Birmingham and received his Ph.D. in Bio-Organic Chemistry. From there, Dr. Vaezi went to the University of Alabama School of Medicine where he received his MD degree in 1992. He completed a four-year academic residency in internal medicine in program focused on clinical research at the University of Alabama Hospitals in Birmingham Alabama. Subsequently, he completed his fellowship in Gastroenterology at the Cleveland Clinic Foundation where he was elected as the Chief Fellow. He also received a Master’s in Epidemiology and Clinical Research from Case Western Reserve University.
Dr. Vaezi is an associate member of the American Gastroenterological Association and a Master of the American College of Gastroenterology.
Disclosures
Dr. Vaezi reports the following:- Off label PPI use and dosage
- Consulting:
- Diversatek; Phathom Pharm.; IsoThrive; Sanofi
- MI Technology patent co-owned by Vanderbilt and Diversatek
- Litigations on role of acid suppressive therapies and adverse events